Transforming glaucoma diagnosis and management with the power of oculomics

Glaucoma is globally a leading cause of irreversible blindness, characterized by progressive optic nerve damage and visual field loss, often associated with elevated IOP. Traditionally, glaucoma treatment strategies primarily focus on lowering IOP. However, recent advancements in oculomics (the study of genomic, proteomic, and metabolomic data related to ocular health) offer new insights into glaucoma pathophysiology, diagnosis, and management.¹ This article will examine the role of oculomics in understanding and managing glaucoma, highlighting recent research advancements, potential clinical applications, and challenges in integrating these technologies into standard ophthalmic practice.²

Glaucoma is a heterogeneous group of eye diseases that causes damage to the optic nerve, leading to vision loss. It is estimated that the number of people with glaucoma (ages 40-80 years) will reach 112 million by the year 2040. Glaucoma treatment currently focuses on the reduction of IOP.³ The limitations of current therapeutic approaches necessitate a better understanding of the underlying mechanisms of the disease process. Therefore, oculomics presents a new paradigm for the diagnosis and management of glaucoma.

Glaucoma encompasses a variety of conditions, with primary open-angle glaucoma (POAG) being the most common form. It is characterized by a slow and progressive loss of peripheral vision, often without obvious symptoms until significant damage occurs. Other forms of glaucoma, such as angle-closure glaucoma, can present acutely with symptoms such as ocular pain and vision changes. Understanding the specific type of glaucoma is critical for determining the appropriate management strategy.

The pathophysiology of glaucoma involves a complex interplay of genetic, environmental, and biomechanical factors that lead to optic nerve degeneration. Elevated IOP is a significant risk factor; however, not all individuals with elevated IOP develop glaucoma. Other contributing mechanisms, such as vascular dysregulation and neuroinflammation, have long been the subject of glaucoma research.⁴

Current pharmacological treatments

The cornerstone of glaucoma management involves the use of topical medications aimed at reducing IOP. Common classes of medications include the following:

Prostaglandin analogs: These medications are often the first-line treatments due to their effectiveness in reducing IOP by increasing uveoscleral outflow.

Beta-blockers: These medications decrease aqueous humor production and are often used in combination with other antiglaucoma medications.

Alpha agonists and carbonic anhydrase inhibitors: These medications can be used to further lower IOP, particularly in patients who do not achieve target pressure with other antiglaucoma drugs.⁵

Despite the efficacy of these medications, adherence has always been a significant challenge because of adverse effects, complex dosing regimens, and patient perception.

Surgical interventions

When pharmacological therapy fails to achieve adequate IOP control, surgical options become essential. Procedures can range from traditional trabeculectomy, which creates a filtration bleb to enhance aqueous outflow, to newer minimally invasive glaucoma surgeries that offer a safer profile with quicker recovery times. Laser procedures are also quite common (eg, selective laser trabeculoplasty, which uses targeted light pulses to clear blockages in the trabecular meshwork, and laser peripheral iridotomy, which creates a small hole in the iris to allow fluid to flow freely and prevent IOP spikes) and are used primarily for narrow-angle glaucoma. The choice of surgical intervention is influenced by the type of glaucoma, the severity of the disease, and patient-specific factors.⁶

The potential role of oculomics in glaucoma

Oculomics leverages various artificial intelligence (AI) technologies to analyze biological data specific to eye health (ie, biomarkers). As previously mentioned, its components include genomics, proteomics, metabolomics, and other molecular techniques that provide insights into diseases such as glaucoma.⁷

Genomics: Studies have identified various genetic markers associated with glaucoma risk, enabling a better understanding of hereditary patterns and risk profiling.

Proteomics: This examines proteins in the eye to identify potential biomarkers for disease and therapeutic targets.

Metabolomics: Analyzing metabolic changes in ocular fluids may reveal alterations associated with glaucomatous processes.

Clinical applications in glaucoma management

Oculomics provides future opportunities for the personalized treatment of glaucoma. Genetic profiling can help identify individuals at risk and tailor therapeutic strategies accordingly. Biomarkers identified through proteomic studies may improve the early detection of glaucoma, allowing for timely intervention rather than relying on traditional methods of glaucoma diagnosis.⁸

Recent genomic studies have unveiled polymorphisms in genes such as MYOC, which is implicated in POAG and juvenile open-angle glaucoma, suggesting that genetic testing may have future applications to glaucoma diagnosis and management. Furthermore, proteomic research has identified various proteins associated with optic nerve degeneration, such as matrix metalloproteinases, offering potential therapeutic targets within these pathways.⁹ The American Academy of Ophthalmology created a task force in 2014 to make recommendations for ophthalmic genetic testing.There have been no changes since 2014, as we are in the early days of genetic testing for glaucoma. Currently, it is only recommended that genetic testing be done for congenital or juvenile glaucoma.¹⁰

Challenges and limitations

Although oculomics provides promising insights into glaucoma management, several challenges remain, including the following:

Technological hurdles: The integration of advanced genomic and proteomic technologies into routine clinical practice requires substantial investment and training for health care professionals.

Clinical validation: Many biomarkers identified through research need extensive validation in diverse populations before they can be implemented in clinical settings.

Ethical considerations: Genetic testing raises ethical concerns regarding privacy, potential discrimination, and the psychological impact on patients.

The future of oculomics in glaucoma management involves several promising avenues for research and application, including the following:

Innovative therapies: The identification of specific genetic pathways may pave the way for targeted gene therapies, decreasing disease progression or modifying disease risk.

AI: Incorporating AI into oculomics can enhance data analysis, improve diagnostic accuracy, and personalize treatment approaches using large data sets.

Holistic approaches: Moving toward personalized medicine that incorporates genetic, proteomic, and environmental factors will improve patient outcomes and ensure a more comprehensive approach to glaucoma management.

Oculomics represents a potential transformative approach to understanding and managing glaucoma. With genomic, proteomic, and metabolomic data, clinicians can improve early detection, personalize treatment plans, and potentially discover new therapeutic avenues. Continued research and collaboration among scientists and clinicians are important in overcoming existing challenges and integrating oculomics into clinical practice.

References

1. Ittoop SM, Jaccard N, Lanouette G, Kahook MY. The role of artificial intelligence in the diagnosis and management of glaucoma. J Glaucoma. 2022;31(3):137-146. doi:10.1097/IJG.0000000000001972

2. Lee AY. The path forward for oculomics and AI. Ophthalmology Times. January 27, 2025. Accessed May 26, 2026. https://www.ophthalmologytimes.com/view/the-path-forward-for-oculomics-and-ai

3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013

4. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192

5. Lee HP, Tsung TH, Tsai YC, Chen YH, Lu DW. Glaucoma: current and new therapeutic approaches. Biomedicines. 2024;12(9):2000. doi:10.3390/biomedicines12092000

6. Lim R. The surgical management of glaucoma: a review. Clin Exp Ophthalmol. 2022;50(2):213-231. doi:10.1111/ceo.14028

7. Hanyuda A, Raita Y, Ninomiya T, et al. Metabolomic profiling of open-angle glaucoma etiologic endotypes: Tohoku multi-omics glaucoma study. Invest Ophthalmol Vis Sci. 2024;65(13):44. doi:10.1167/iovs.65.13.44

8. Beykin G, Goldberg JL. Molecular biomarkers for glaucoma. Curr Ophthalmol Rep. 2019;7(3):171-176. doi:10.1007/s40135-019-00213-0

9. Dorgeloh K, Wong TA. Inside genetics and glaucoma. Optometry Times. August 28, 2025. Accessed May 26, 2026. https://www.optometrytimes.com/view/inside-genetics-and-glaucoma

10. American Academy of Ophthalmology Task Force on Genetic Testing. Recommendations for Genetic Testing of Inherited Eye Diseases - 2014. American Academy of Ophthalmology. February 2014. Accessed May 26, 2026. https://www.aao.org/education/clinical-statement/recommendations-genetic-testing-of-inherited-eye-d